News
ZEAL
17.59
0.00%
0.00
BUZZ-Guggenheim downgrades Altimmune as 'ship has likely sailed' for obesity drug
Shares of drug developer Altimmune fall 5.8% to $6.84 premarket. Brokerage Guggenheim downgrades stock to 'buy' from 'buy', removes PT on the stock. Says 'ship has likely sailed' for obesity drug pemvidutide.
Reuters · 5d ago
FACTBOX-Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
Madrigal Pharmaceuticals' drug wins first US approval for fatty liver disease NASH. Madrigal's drug is the first to win regulatory approval to treat a serious type of liver disease. Other companies are also developing treatments for the disease. The race to tap a multi-billion dollar market is intensifying.
Reuters · 03/14 20:09
FACTBOX-Novo Nordisk brings new contender in race for blockbuster obesity drugs
Novo Nordisk and Eli Lilly are the leaders in the weight-loss drug market. The market is estimated to be worth $100 billion by the end of the decade. Novo's drug amycretin helped obese patients achieve 13.1% weight loss after 12 weeks.
Reuters · 03/07 12:45
UPDATE 1-European shares fall over lacklustre Chinese stimulus, economic data in focus
European shares fall over lacklustre Chinese stimulus, economic data in focus. The pan-European STOXX 600 was down 0.3% after settling just below all-time highs on Monday. China pledges to transform its economy failed to impress investors. Euro zone and U.S. Economic data due today.
Reuters · 03/05 09:35
EUROPE RESEARCH ROUNDUP-Direct Line Insurance, Hammerson, Mercedes Benz Group AG
Analysts revise their ratings and price targets on several European companies. Direct Line Insurance, Hammerson and Mercedes Benz Group AG among those. Campari, Airbus and BAE Systems among companies to see share price moves. European markets are closed on Wednesday for the World Cup in Brazil.
Reuters · 02/28 07:21
FACTBOX-Drugmakers deepen efforts to tap into booming market for obesity drugs
Viking Therapeutics says its experimental drug helped patients with obesity achieve "significant" weight loss in a mid-stage study. Novo Nordisk and Eli Lilly are so far the leaders in the weight-loss drug market. The market is estimated to be worth $100 billion by the end of the decade.
Reuters · 02/27 18:15
BUZZ-Altimmune up after rival Zealand's obesity drug shows promise in fatty-liver patients
Altimmune up after rival Zealand's obesity drug shows promise in fatty-liver patients. Shares of drug developer Altimmune rise 13.8% to $10.47 in premarket trading. Zealand Pharma reports "groundbreaking" mid-stage trial results for an experimental drug for a type of fatty liver.
Reuters · 02/26 14:17
UPDATE 1-Commodity-linked stocks drag European equities lower
European shares fall on Monday, led by a decline in commodity-linked stocks. The pan-European STOXX 600 was down 0.4%, on track for the biggest one day drop in two weeks. Basic resources sub-index leads losses as oil and gas stocks fall. Euro zone, U.S. Inflation data in focus this week.
Reuters · 02/26 10:18
UPDATE 1-Zealand Pharma shares surge on liver disease drug trial data
Zealand Pharma shares surge on liver disease drug trial data. Zealand shares hit a record high and were the best performer on the STOXX Europe 600. The company is developing an experimental obesity treatment with Boehringer Ingelheim. The drug meets its primary and key secondary endpoints in the treatment of fatty liver.
Reuters · 02/26 09:10
BUZZ-Zealand Pharma slips on read-across from Eli Lilly forecast
Zealand Pharma slips on read-across from Eli Lilly forecast. Shares of Zealand Pharma ZELA.CO are trading at 4.4% lower after falling as much as 7.7% this morning. Eli Lilly & Co forecast a 2024 profit above Wall Street estimates.
Reuters · 02/07 15:19
UPDATE 1-European shares flat as healthcare, energy stocks offsets earnings bump
European shares flat as healthcare, energy stocks offsets earnings bump. The pan-European STOXX 600 index was unchanged at 486.66 points. German industrial production falls more than expected in December. Wind turbine maker Vestas rises after beating Q4 earnings forecasts. Handelsbanken gains on higher-than-expected dividend.
Reuters · 02/07 10:10
FACTBOX-Drugmakers deepen efforts to tap into booming market for obesity drugs
Drugmakers deepen efforts to tap into booming market for obesity drugs. Novo Nordisk and Eli Lilly are so far the leaders in the weight-loss drug market. The market is estimated to be worth $100 billion by the end of the decade. The Danish drugmaker is buying Catalent to boost production of its drug Wegovy.
Reuters · 02/06 12:28
UPDATE 1-Weight loss drug windfall attracts pharma companies
Pharma executives from Amgen to Pfizer are plotting to break into the lucrative obesity market. The market is estimated to reach $100 billion at a minimum by the end of the decade. Novo Nordisk's and Eli Lilly's weight-loss drugs are leading the way. The drugs have been shown to reduce weight by 20%.
Reuters · 01/11 18:10
Drugmakers plot way into obesity market with deals and development
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market. At stake is a market estimated to reach $100 billion at a minimum by the end of the decade. Novo Nordisk and Eli Lilly are leading the field with their obesity drugs. Nearly 115 million U.S. Adults and children are obese.
Reuters · 01/11 11:00
US FDA declines to approve Zealand Pharma's drug for low blood sugar in children
US FDA declines to approve Zealand Pharma's drug for low blood sugar in children with a genetic disorder. The drug is for the prevention and treatment of low blood Sugar in children. The U.S. Food and Drug Administration declined to approve the drug for the treatment of the disorder.
Reuters · 12/23/2023 10:03
BUZZ-Zealand Pharma at record high amid upbeat analysts comments post obesity R&D event
Zealand pharma shares rise 5% to record high after obesity r&d event. Danish biotechnology company updated the market on its obesity pipeline. Main focus of event was on drug candidates survodutide, dapiglutide and petrelintide. Nordea: zealand pharma has a highly potent obesity pipeline and is a leading player.
Reuters · 12/06/2023 10:01
FACTBOX-Roche enters obesity drugs race with $2.7 bln Carmot deal
Market for obesity treatments is estimated to be worth $100 billion by the end of the decade. Novo nordisk and eli lilly already dominate the market. Roche has agreed to buy carmot therapeutics for $2.7 billion. Roche is one of several companies in the race to develop obesity drugs.
Reuters · 12/04/2023 12:53
FACTBOX-Pfizer's weight loss ambitions hit roadblock
Pfizer says it is stopping further trials of a twice-daily version of its oral weight-loss drug. Decision comes after most patients in a mid-stage trial dropped out due to side effects. Dozens of drugmakers are rushing to grab a slice of the $100 billion obesity market. Pfizer, eli lilly and novo nordisk are among companies targeting the market.
Reuters · 12/01/2023 13:05
EUROPE RESEARCH ROUNDUP-Biomerieux, Eurofins Scientific, OCI NV
Reuters · 09/29/2023 07:04
EUROPE RESEARCH ROUNDUP-Adyen NV, Prosus NV, Spectris
Reuters · 08/18/2023 07:05
More
Webull provides a variety of real-time ZEAL stock news. You can receive the latest news about Zealand Pharma A/S through multiple platforms. This information may help you make smarter investment decisions.
About ZEAL
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.